{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:12:18Z","timestamp":1778213538846,"version":"3.51.4"},"reference-count":13,"publisher":"Jaypee Brothers Medical Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.59556\/japi.74.1337","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:01:41Z","timestamp":1778212901000},"page":"e1-e5","source":"Crossref","is-referenced-by-count":0,"title":["Sodium\u2013Glucose Cotransporter 2 Inhibitors in Kidney Diseases Other Than That Due to Diabetes: Benefits in Composite Renal Outcomes Driven by Immunoglobulin A Nephropathy"],"prefix":"10.59556","volume":"74","author":[{"given":"Subhankar","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhurima","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradip","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujoy","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"key":"key20260508040135_B1","doi-asserted-by":"crossref","first-page":"2295\u2013","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380:","author":"Perkovic","year":"2019;","journal-title":"N Engl J Med"},{"key":"key20260508040135_B2","doi-asserted-by":"crossref","first-page":"1436\u2013","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383:","author":"Heerspink","year":"2020;","journal-title":"N Engl J Med"},{"key":"key20260508040135_B3","doi-asserted-by":"crossref","first-page":"117\u2013","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388:","author":"The EMPA-KIDNEY Collaborative Group,","year":"2023;","journal-title":"N Engl J Med"},{"key":"key20260508040135_B4","doi-asserted-by":"crossref","first-page":"22\u2013","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.","volume":"9:","author":"Wheeler","year":"2021;","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20260508040135_B5","doi-asserted-by":"crossref","first-page":"51\u2013","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.","volume":"12:","author":"Abat","year":"2024;","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20260508040135_B6","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(25)00222-0","article-title":"Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.","author":"Herrington","year":"2025.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20260508040135_B7","doi-asserted-by":"crossref","first-page":"215\u2013","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.","volume":"100:","author":"Wheeler","year":"2021;","journal-title":"Kidney Int"},{"key":"key20260508040135_B8","doi-asserted-by":"crossref","first-page":"1647\u2013","DOI":"10.1093\/ndt\/gfab335","article-title":"Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.","volume":"37:","author":"Wheeler","year":"2022;","journal-title":"Nephrol Dial Transplant"},{"key":"key20260508040135_B9","doi-asserted-by":"crossref","first-page":"1317\u2013","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.","volume":"37:","author":"Herrington","year":"2022;","journal-title":"Nephrol Dial Transplant"},{"key":"key20260508040135_B10","doi-asserted-by":"crossref","first-page":"S117\u2013","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.","volume":"105:","author":"Stevens","year":"2024;","journal-title":"Kidney Int"},{"key":"key20260508040135_B11","doi-asserted-by":"crossref","first-page":"1700\u2013","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.","volume":"35:","author":"Wheeler","year":"2020;","journal-title":"Nephrol Dial Transplant"},{"key":"key20260508040135_B12","doi-asserted-by":"crossref","first-page":"1399881.","DOI":"10.3389\/fphar.2024.1399881","article-title":"Pharmacological targets of SGLT2 inhibitors on IgA nephropathy and membranous nephropathy: a mendelian randomization study.","volume":"15:","author":"Lv","year":"2024;","journal-title":"Front Pharmacol"},{"key":"key20260508040135_B13","doi-asserted-by":"crossref","first-page":"582\u2013","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomized, double-blind, crossover trial.","volume":"8:","author":"Cherney","year":"2020;","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:01:46Z","timestamp":1778212906000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-4-e1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.59556\/japi.74.1337"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1337","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}